Opinion|Videos|July 29, 2024

Dose Modifications & Patient Adherence Strategies for Managing Toxicities CDK 4/6 Inhibitors

A panel of experts discuss the variables of dosage and patient adherence in regards to managing toxicities from CDK4/6 inhibitors.

Video content above is prompted by the following question(s):

  • What is the impact of dose modifications or interruptions on treatment outcomes with CDK4/6 inhibitors in the adjuvant setting?
  • What has your experience been with toxicities and their management impacting patient adherence to CDK4/6 inhibitors in the adjuvant setting, and what strategies have you used to help improve this?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.


Latest CME

Brand Logo

259 Prospect Plains Rd, Bldg H
Monroe, NJ 08831

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo